



Atty. Dkt. No. 065691-0424

IFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Jacques MIGEON et al.

Title: USE OF ALVERINE, ALONE OR IN  
COMBINATION WITH A TRICYCLIC  
ANTIDEPRESSANT OR AN  
ANTIDEPRESSANT WHICH IS A SPECIFIC  
INHIBITOR OF SEROTONIN REUPTAKE  
FOR TREATMENT OF DEPRESSION

Appl. No.: 10/560,449

International Filing Date: 6/11/2004  
371(c) Date: 3/21/2006

Examiner: Unassigned

Art Unit: 1615

Conf. No.: 6548

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**


The relevance of the listed documents is described in the present specification or in the International Search Report, a copy of which was previously submitted. English language abstracts of each foreign language reference are provided. Document B2 is equivalent to foreign-language Document B5. The absence of a full English translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date OCT 10 2006

By 

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

OCT 10 2006

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Date Submitted:

OCT 10 2006

(use as many sheets as necessary)

## **Complete if Known**

Application Number	10/560,449
Filing Date	6/11/2004
First Named Inventor	Jacques MIGEON
Group Art Unit	1615
Examiner Name	Unassigned
Attorney Docket Number	065691-0424

Sheet

1

of

1

## **U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	B1	6,239,126		ZHANG et al.	05-29-2001	
	B2	6,335,368		LIVIERO et al.	01-01-2002	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B3	WO	92/02488	A	NORGINE LTD.	02-20-1992		
	B4	GB	2 272 155	A	BROTHER LTD.	05-11-1994		
	B5	FR	2 798 590	A	OREAL	03-23-2001		A

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B6	COELHO et al., "Rectal Antinociceptive Properties of Alverine Citrate are Linked to Antagonism at the 5-HT1A Receptor Subtype," Journal of Pharmacy and Pharmacology, Vol. 53, No. 10, October 2001, pgs. 1419-1426.	
	B7	KÜLZ et al., report 72, pp. 2161-2167, No. 12/1939 (abstract included).	A
	B8	BORSINI et al., "Is the forced swimming test a suitable model for revealing antidepressant activity?", Psychopharmacology, vol. 94, pp. 147-160, 1988.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.